The 20 Best Muscle Invasive Bladder Cancer Doctors Near Me

Dr. Sima Porten is a specialist in cancers of the genital and urinary organs. She is a member of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center. Her clinical interests include the diagnosis and treatment of genitourinary cancer, particularly bladder cancer, upper tract urothelial cancer, kidney cancer and high-risk prostate cancer. Porten's research focuses mainly on the diagnosis and management of urothelial carcinoma, a cancer involving parts of the kidney, bladder and ureter (the tube connecting each kidney to the bladder). In studying the biologic or genetic basis of urothelial carcinoma, she hopes to develop new tests and treatments to bring personalized medicine to patients with bladder cancer. Porten received her undergraduate, medical and master of public health degrees from Northwestern University. During medical school, she was inducted into the Alpha Omega Alpha Honor Medical Society and also completed a fellowship through the Howard Hughes Medical Institute–National Institutes of Health Research Scholars Program. She then completed her urology residency training at UCSF, where she received the Julius R. Krevans Award for Clinical Excellence. During her training in urologic oncology at the University of Texas MD Anderson Cancer Center, she was awarded a John Quale Travel Fellowship for her research in bladder cancer. Porten is an active member of the American Urological Association, American Society of Clinical Oncology, Society of Women in Urology and Society of Urologic Oncology. Dr. Porten is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Porten is board certified in American Board Of Urology, Urology. Dr. Porten is currently accepting new patients.

Sumanta Pal is an Oncologist practicing medicine in Duarte, California. Dr. Pal is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Hossein Borghaei is an Oncologist and a Radiologist practicing medicine in Philadelphia, Pennsylvania. Dr. Borghaei is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Borghaei is board certified in American Board Of Internal Medicine - Medical Oncology.

Tanya Dorff is an Oncologist practicing medicine in Duarte, California. Dr. Dorff is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Penile Cancer, Familial Prostate Cancer, Prostatectomy, and Orchiectomy.

Elizabeth Plimack is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Plimack is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy. Dr. Plimack is board certified in American Board Of Internal Medicine - Medical Oncology.

Rana Mckay is an Oncologist practicing medicine in La Jolla, California. Dr. Mckay is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy. Dr. Hahn is currently accepting new patients.

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic. He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer. Dr. Lerner is author of more than 160 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. Dr. Lerner is an active member of the prestigious American Association of Genitourinary surgeons and is listed routinely among America's Top Doctors and Best Doctors in America. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor, and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, targeted molecular therapeutics, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 22 years of experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy for muscle invasive bladder cancer. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, co-chair of the NCI's Bladder Cancer Task Force and the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy. Dr. Lerner is currently accepting new patients.

Moshe Ornstein is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 21 years. Dr. Ornstein is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Gamma Knife Radiosurgery. Dr. Ornstein is board certified in American Board Of Internal Medicine, 2017. Dr. Ornstein is currently accepting new patients.

David Mcdermott is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Mcdermott is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Melanoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy. Dr. Mcdermott is board certified in American Board Of Internal Medicine. Dr. Mcdermott is currently accepting new patients.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman-Censits is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Bladder Reconstruction. Dr. Hoffman-Censits is board certified in American Board Of Internal Medicine. Dr. Hoffman-Censits is currently accepting new patients.

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Colonoscopy. Dr. Azad is board certified in American Board Of Internal Medicine. Dr. Azad is currently accepting new patients.

Asheesh Shipstone is a Hematologist and an Oncologist practicing medicine in Kingsport, Tennessee. Dr. Shipstone is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 45 other conditions, according to our data. His clinical expertise encompasses Adult Immune Thrombocytopenia, Colorectal Cancer, Hemangioma Thrombocytopenia Syndrome, and Thrombocytopenia. Dr. Shipstone is board certified in American Board Of Internal Medicine. Dr. Shipstone is currently accepting new patients.

Jacob Sands is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Sands is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Sands is board certified in Medical Oncology. Dr. Sands is currently accepting new patients.

Morgan Roupret practices practicing medicine in Paris, France. Mr. Roupret is rated as an Elite expert by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Bladder Cancer, Nephrectomy, and Cystectomy.

Joel Neal is an Oncologist practicing medicine in Palo Alto, California. Dr. Neal is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Thymic Epithelial Tumor, and Tissue Biopsy.

Dr. Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor MI. Dr. Vaishampayan is a Professor of Internal Medicine and her research is primarily in translational drug development and early phase clinical trials in cancer with a focus on genitourinary malignancies. She has initiated, obtained funding for, and conducted and published many investigator initiated trials with embedded biomarkers and established multidisciplinary collaboration. She has served as site PI of the UO-1 Early Therapeutics Research Grant at Wayne State University. She was also the chair of the solid tumor division of oncology at WSU. She has completed formal leadership traning course and is Fellow of the Advisory Board (FAB). She is the appointed chair of the Advanced Renal committee of SWOG and a member of the Renal task force of the NCI. She is a board member of the Michigan Society of Hematology/Oncology (MSHO) and organizes annual board review course. Additionally, she has served as track leader for the ASCO education committee GU non prostate (Renal and bladder cancer) track. Dr. Vaishampayan attended Wayne State University for her residency and fellowship completion and attended medical school at Byramjee Jeejeebhoy in Pune, India and completed a higher secondary certificate in the field of science at Fergusson College in Pune, India.In her free time, Dr. Vaishampayan enjoys reading, dance, music and travel. Travel, reading (mysteries preferred), follows football. Dr. Vaishampayan is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. She is also highly rated in 32 other conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Orchiectomy. Dr. Vaishampayan is board certified in Medical Oncology. Dr. Vaishampayan is currently accepting new patients.

Ajjai Alva is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Alva is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Lymphadenectomy, and Nephrectomy. Dr. Alva is currently accepting new patients.

Daniel Castellano practices practicing medicine in Madrid, Spain. Mr. Castellano is rated as an Elite expert by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Renal Cell Carcinoma (RCC), Neuroendocrine Tumor, Cystectomy, and Orchiectomy.

Dr. Vadim S. Koshkin is a genitourinary oncologist who specializes in caring for adults with bladder, prostate, kidney and testicular cancers. His personal enthusiasm for travel informs his approach to care, as he likes to hear about where his patients come from in order to better understand who they are. In his research, Koshkin designs and carries out clinical trials of treatments for bladder and prostate cancers. He has a particular focus on the role of immunotherapy, or treatments that stimulate a patient's own immune system to help fight cancer. He also studies targeted treatments that are aimed against specific mutations in the DNA of tumor cells, which make these tumors more vulnerable to particular drugs. This allows for the delivery of personalized treatment based on individual characteristics of patients and their tumors. After earning his medical degree at the University of Chicago Pritzker School of Medicine, Koshkin completed a residency in internal medicine at the University of Michigan. He then completed a fellowship in hematology and oncology at the Cleveland Clinic. He belongs to the American Society of Clinical Oncology, American Association for Cancer Research and Bladder Cancer Advocacy Network. A history and trivia buff, Koshkin loves to read. He also follows soccer and Chicago sports teams in his free time. Dr. Koshkin is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Non-Muscle Invasive Bladder Cancer, and Lymphadenectomy. Dr. Koshkin is board certified in American Board Of Internal Medicine, Medical Oncology and American Board Of Internal Medicine, Internal Medicine. Dr. Koshkin is currently accepting new patients.